Aurinia Pharmaceuticals Inc (AUPH) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 4 Margin 4 Expansion 3 Platform 2 Financial 4

latest quarter score

Earnings Reports

17
Aurinia Pharmaceuticals (AUPH) Q4 2025: Loopkindness Drives 25% Sales Growth, Guidance Bakes in Competitive Shifts
February 26, 2026
20
Aurinia Pharmaceuticals (AUPH) Q3 2025: LoopKindness Sales Up 27% as Guidance Rises Again on Clinical Momentum
November 04, 2025
8
Aurinia (AUPH) Q2 2025: Phase 1 R-Tintercept Cuts IgA by 48%, Paving Path for Autoimmune Expansion
July 31, 2025
16
Aurinia (AUPH) Q1 2025: 25% Lupkynis Growth Drives $12M Operating Cash Flow Turnaround
July 06, 2025
Aurinia Pharmaceuticals (AUPH) Q4 2024: 36% Lupkynis Sales Growth Drives Positive Cash Flow Turnaround
February 27, 2025
AUPH Q3 2024: $40M Cost Reset and 45% Workforce Cut Signal Leaner Growth Playbook
November 07, 2024
Aurinia (AUPH) Q2 2024: Patient Base Grows 22% as Cash Flow Turns Positive
August 01, 2024
AUPH Q1 2024: Lupkynis Per-Patient Revenue Climbs 15% as Persistency Rises, Restructuring Accelerates Cash Flow Turnaround
May 02, 2024
Aurinia Pharmaceuticals (AUPH) Q4 2023: $55M Cost Cut Reshapes Focus on Lupkynis Execution
February 15, 2024
15
AUPH Q3 2023: Lupkynis Net Revenue Jumps 60% as Persistency, Guidelines, and Globalization Drive Next Phase
November 02, 2023
Aurinia Pharmaceuticals (AUPH) Q2 2023: Persistency Climbs to 54%, Extending Revenue Runway for Lupkynis
August 03, 2023
Aurinia Pharmaceuticals (AUPH) Q1 2023: LuKinus Drives 61% Patient Growth, Guidance Raised Amid Commercial Execution
May 04, 2023
Aurinia Pharmaceuticals (AUPH) Q4 2022: Patient Start Forms Up 9% as Commercial Execution Accelerates
February 28, 2023

Browse all companies